Californian immuno-oncology biotech CG Oncology has reeled in a $47 million series D—and, surely, an IPO isn’t far behind—as it looks to phase 3 trials. The funding was led by new investor ...

Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment with a current market capitalization of $803 million, has been making ...

Headquartered in Shenzhen, China, Synthetica is a biotech company founded in 2023 ... Our innovative synthetic biology approach to developing oncolytic bacteria offers new hope for more effective ...

CORAL GABLES, FLORIDA, UNITED STATES, February 1, 2023 /EINPresswire.com/ -- Adze Biotechnology Granted Patent for its Proprietary Oncolytic Adenovirus Platform. Adze ...

Genelux Corporation (NASDAQ:GNLX) has made great progress in advancing the use of oncolytic virus-based immunotherapy ... who runs the Biotech Analysis Central pharmaceutical service on Seeking ...

Called ONCOTECH, it combines oncolytic virotherapy and adoptive T cell therapy for treatment of patients with cancerous tumors. The study is published in the journal Nature Biotechnology.

Oncolytics Biotech reports preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with CAR T cell therapy in solid tumors. News release. Oncolytics Biotech, Inc ...

AbbVie has secured an option on three of Turnstone Biologics’ oncolytic viral immunotherapies. The deal gives AbbVie the chance to add Turnstone’s lead MAGEA3 candidate to its pipeline once ...

SAN DIEGO and CALGARY, Alberta, May 29, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic ...

This complimentary report offers biotech and pharmaceutical companies, data-driven analysis to navigate the complexities of clinical trials and regulatory frameworks in oncolytic virus therapy.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype ...